rimorphin and Alzheimer-Disease

rimorphin has been researched along with Alzheimer-Disease* in 2 studies

Other Studies

2 other study(ies) available for rimorphin and Alzheimer-Disease

ArticleYear
Dysregulation of dynorphins in Alzheimer disease.
    Neurobiology of aging, 2007, Volume: 28, Issue:11

    The opioid peptides dynorphins may be involved in pathogenesis of Alzheimer disease (AD) by inducing neurodegeneration or cognitive impairment. To test this hypothesis, the dynorphin system was analyzed in postmortem samples from AD and control subjects, and subjects with Parkinson or cerebro-vascular diseases for comparison. Dynorphin A, dynorphin B and related neuropeptide nociceptin were determined in the Brodmann area 7 by radioimmunoassay. The precursor protein prodynorphin, processing convertase PC2 and the neuroendocrine pro7B2 and 7B2 proteins required for PC2 maturation were analyzed by Western blot. AD subjects displayed robustly elevated levels of dynorphin A and no differences in dynorphin B and nociceptin compared to controls. Subjects with Parkinson or cerebro-vascular diseases did not differ from controls with respect to any of the three peptides. PC2 levels were also increased, whereas, those of prodynorphin and pro7B2/7B2 were not changed in AD. Dynorphin A levels correlated with the neuritic plaque density. These results along with the known non-opioid ability of dynorphin A to induce neurodegeneration suggest a role for this neuropeptide in AD neuropathology.

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Dynorphins; Endorphins; Female; Humans; Male; Nerve Degeneration; Nociceptin; Opioid Peptides; Up-Regulation

2007
Endogenous opioids in frontal cortex of patients with Down syndrome.
    Neuroscience letters, 1996, Jan-19, Volume: 203, Issue:2

    The main purpose of this study was to investigate differences regarding endogenous opioids in post-mortem frontal cortex of adult patients with Down syndrome (DS), patients with Alzheimer disease (AD) and neurologically healthy persons, respectively, using specific radioimmunoassays. The results of this study show that there is an increase in the levels of leu-enkephalin and dynorphin A in the frontal cortex of patients with DS as compared to the control group. An almost identical increase was also observed when comparing patients with AD to controls. In conclusion, the results of this study suggest a relationship between elevated tissue levels of leuenkephalin and dynorphin A in cerebral cortex and cognitive impairments in patients with DS and AD.

    Topics: Aged; Alzheimer Disease; Down Syndrome; Dynorphins; Endorphins; Enkephalin, Leucine; Enkephalin, Methionine; Enkephalins; Female; Frontal Lobe; Gene Expression Regulation; Humans; Male; Middle Aged; Protein Precursors; Radioimmunoassay

1996